[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:retinitis-pigmentosa":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":133,"states":134},"Retinitis Pigmentosa",20,16,[8,16,22,29,35,41,47,53,59,65,71,77,83,89,95,101,107,114,120,127],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04278131","BS01 in Patients With Retinitis Pigmentosa",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:19:09.651016Z","2026-05-05T02:43:29.044564Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06891885","A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa",[12],"2026-08-26T02:18:14.396999Z","2026-05-05T02:43:27.060444Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT06319872","The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration",[26],"Phase 1","2026-08-26T02:16:38.053590Z","2026-05-05T02:43:27.673519Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT03011541","Stem Cell Ophthalmology Treatment Study II",[],"2026-08-26T02:17:33.002248Z","2026-05-05T02:43:29.077392Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06789445","A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)",[12],"2026-08-26T02:17:28.381459Z","2026-05-05T02:43:26.709807Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT05809635","Study of BEST1 Vitelliform Macular Dystrophy",[],"2026-08-26T02:15:28.524219Z","2026-05-13T02:55:06.377944Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT05589714","Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants",[],"2026-08-26T02:19:26.493949Z","2026-05-13T02:55:06.367833Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT00254605","Retinal Imaging in Patients With Inherited Retinal Degenerations",[],"2026-08-26T02:17:16.126291Z","2026-05-13T02:55:06.032926Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":63,"content_modified":64},"NCT02617966","Rod and Cone Mediated Function in Retinal Disease",[],"2026-08-26T02:18:54.586325Z","2026-05-13T02:55:06.098265Z",{"nct_id":66,"title":67,"phases":68,"status":13,"updated_at":69,"content_modified":70},"NCT07502664","Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)",[],"2026-08-26T02:18:11.042248Z","2026-05-13T02:55:06.711578Z",{"nct_id":72,"title":73,"phases":74,"status":13,"updated_at":75,"content_modified":76},"NCT06375239","Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration",[],"2026-08-26T02:18:40.612983Z","2026-05-13T02:55:06.485355Z",{"nct_id":78,"title":79,"phases":80,"status":13,"updated_at":81,"content_modified":82},"NCT05355415","Adaptive Optics Imaging of Outer Retinal Diseases",[],"2026-08-26T02:18:42.501841Z","2026-05-13T02:55:06.301322Z",{"nct_id":84,"title":85,"phases":86,"status":13,"updated_at":87,"content_modified":88},"NCT02435940","Inherited Retinal Degenerative Disease Registry",[],"2026-08-26T02:16:07.529922Z","2026-05-13T02:55:06.097266Z",{"nct_id":90,"title":91,"phases":92,"status":13,"updated_at":93,"content_modified":94},"NCT01866371","High Resolution Retinal Imaging",[],"2026-08-26T02:17:30.961790Z","2026-05-13T02:55:06.078191Z",{"nct_id":96,"title":97,"phases":98,"status":13,"updated_at":99,"content_modified":100},"NCT01432847","Cell Collection to Study Eye Diseases",[],"2026-08-26T02:17:25.718160Z","2026-05-13T02:55:06.073476Z",{"nct_id":102,"title":103,"phases":104,"status":13,"updated_at":105,"content_modified":106},"NCT03635645","Experimental and Clinical Studies of Retinal Stimulation",[],"2026-08-26T02:18:59.761994Z","2026-05-05T02:43:29.384517Z",{"nct_id":108,"title":109,"phases":110,"status":111,"updated_at":112,"content_modified":113},"NCT05748873","Promising ROd-cone DYstrophy Gene therapY",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T02:23:21.062956Z","2026-05-05T02:43:29.698837Z",{"nct_id":115,"title":116,"phases":117,"status":111,"updated_at":118,"content_modified":119},"NCT06852963","A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001",[12],"2026-08-03T02:19:54.166214Z","2026-05-05T02:43:28.987926Z",{"nct_id":121,"title":122,"phases":123,"status":111,"updated_at":125,"content_modified":126},"NCT06627179","Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene",[124],"Phase 2","2026-08-03T02:09:19.831034Z","2026-05-05T02:43:27.990569Z",{"nct_id":128,"title":129,"phases":130,"status":111,"updated_at":131,"content_modified":132},"NCT06912633","Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)",[124],"2026-08-03T02:28:34.088585Z","2026-05-05T02:43:26.723909Z",[],[135,139,142,146,150,153,157,160,163,167],{"state":136,"count":137,"slug":138},"California",7,"california",{"state":140,"count":137,"slug":141},"Florida","florida",{"state":143,"count":144,"slug":145},"Texas",6,"texas",{"state":147,"count":148,"slug":149},"Maryland",5,"maryland",{"state":151,"count":148,"slug":152},"Pennsylvania","pennsylvania",{"state":154,"count":155,"slug":156},"Massachusetts",4,"massachusetts",{"state":158,"count":155,"slug":159},"Michigan","michigan",{"state":161,"count":155,"slug":162},"Oregon","oregon",{"state":164,"count":165,"slug":166},"New York",3,"new-york",{"state":168,"count":165,"slug":169},"Wisconsin","wisconsin"]